Skip to content

INNOVENTIS PHARMA

Active Public limited companyfounded 2018active for 8 yearsVierschaar 6, 9250 WaasmunsterKBO/BCE: BE 0690.813.115

Board

1 director, no change since 2024
Sole director
appointed by deed of 27-02-2024 term without a fixed end
earlier director, until 27-02-2024
Signing authorityThe articles say who may bind the company, for example by signing a contract.
“de vennootschap in en buiten rechte rechtsgeldig verbonden door twee (2) gezamenlijk handelende bestuurders of door één (1) gedelegeerd bestuurder alleen handelend.”
deed of 23-02-2018

Office holders in the KBO →

Mandates through the years

1 name, the dashed line is today

Sole director
BoardEarliermandate already running before its first mention
Mandates as a list
    • Sole director, appointed by deed of 27-02-2024, still in office
    • Director, until 27-02-2024
With Starter you also see 3 former office holders in the mandate history. See the plans →

Control

Founders
,
This company
INNOVENTIS PHARMA
Equity €396,169
Profit €1,561 in 2025

Capital

Capital
€561,500
Shares
22,825
Contribution per share
€24.60
Equity per share
€17.36 in 2025
Source
deed of 27-02-2024

Articles of association

deed of 27-02-2024 (in Dutch)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Board ruleThese rules set how the board is made up, meets and takes decisions.
1 director
Kind of sharesThe articles set which classes of shares exist and what rights each class carries.
Soort A Aandelen
Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
EUR
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
“Organisatie en bijeenroeping De gewone algemene vergadering wordt jaarlijks gehouden op de laatste werkdag van mei…”

Founders

At incorporation deed of 23-02-2018 ↗
  • founder
  • founder

Capital transactions

Capital over time
  1. 27-02-2024 Capital increase of €500,000 · to €561,500 · 20,325 new shares, 89% of the 22,825 shares after the increase · “inbreng (deel) schuldvordering”
  2. 23-02-2018 Incorporation · €61,500 · 2,500 shares

Next steps